Protocol Ledger

NCT07029828 · Phase III · RECRUITING

A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.

Interventional Phase III clinical trial protocol NCT07029828 sponsored by Pfizer in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-09-10 Enrollment: 140 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07029828
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)140 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07029828
Protocol FieldVerified Registry Value
NCT IdentifierNCT07029828
Consolidated Lead SponsorPfizer
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment140 participants (ESTIMATED)
Registered Start Date2025-09-10
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07029828
Hospital Research SiteLocationSite Profile
UCI Health and Chao Family Comprehensive Cancer CenterOrange, CAOpen Hospital Dossier ->
Children's Hospital ColoradoAurora, COOpen Hospital Dossier ->
Dawes Fretzin Clinical Research Group, LLCIndianapolis, INOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI